Streetbeat News

LPTX

Leap Therapeutics, Inc.

https://www.leaptx.com

Industry

Biotechnology

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

HC Wainwright & Co. has reiterated its Buy rating on Leap Therapeutics (NASDAQ:LPTX) and maintained a price target of $5.5.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:09 am

Leap Therapeutics reported a Q2 2024 GAAP EPS of $(0.52), missing the estimate of $(0.43). The company has $78.5M in cash and cash equivalents as of June 30, 2024, which is expected to fund its operations and capital expenditures into Q2 2026.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:25 am

Rodman & Renshaw has initiated coverage on Leap Therapeutics (NASDAQ:LPTX) with a Buy rating and set a price target of $8.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 4:46 pm

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Leap Therapeutics (NASDAQ:LPTX) but lowers the price target from $7 to $5.5.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 11:49 am

Leap Therapeutics announced that the net proceeds from its April 2024 financing of $37.2M, along with its existing cash, cash equivalents, and marketable securities totaling $54.9M, are expected to extend its cash runway into the second quarter of 2026.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:11 am

Leap Therapeutics reported its Q1 2024 GAAP EPS at $(0.51), surpassing the estimated $(0.58).

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 11:09 am

Gilead Sciences, Inc. has reported a 13.9% stake in Leap Therapeutics as of April 10, 2024, according to a 13G filing with the SEC.

Portfolio Pulse from Benzinga Newsdesk

April 19, 2024 | 8:43 pm

Leap Therapeutics' stock price increased following the announcement of a $40 million private placement.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 1:16 pm

Leap Therapeutics has announced a $40 million private placement to raise funds. This strategic financial move is aimed at bolstering the company's capital, potentially to further its research, development, and operational activities.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:33 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. XTL Biopharmaceuticals, Leap Therapeutics, and Jaguar Health were among the top gainers, with increases of 13.9%, 11.21%, and 10.94% respectively. On the downside, Biophytis, Fresh2 Group, and Etao International Co led the losers, with declines of 20.8%, 16.63%, and 14.01% respectively. Notably, Leap Therapeutics' rise followed its Q4 earnings release, and Avinger also reported its Q4 earnings.

Portfolio Pulse from Benzinga Insights

March 20, 2024 | 9:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.